Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | ACP1 | P24666 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092268 | 0.81 | L3MBTL1 (0.63) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL638412 | 0.81 | L3MBTL1 (0.63) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL27492494 | 0.81 | KMT2A (0.64) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL4084496 | 0.80 | L3MBTL1 (0.60) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL637946 | 0.80 | L3MBTL1 (0.60) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL4089423 | 0.77 | NPY5R (0.59) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL7951223 | 0.76 | SLC29A1 (0.41) | TSHRL3MBTL1HSD17B10GAAHPGD | |
| SCHEMBL4097334 | 0.75 | KMT2A (0.61) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL1090785 | 0.74 | L3MBTL1 (1.00) | TSHRL3MBTL1HSD17B10GLAGAA | |
| SCHEMBL1091130 | 0.74 | L3MBTL1 (1.00) | TSHRL3MBTL1HSD17B10GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150757-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-11 | — | — | US | disclosed |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-08 | — | — | US | disclosed |
| US-9522905-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-20 | — | — | US | disclosed |
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9255080-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-09 | — | — | US | disclosed |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-10 | — | — | US | disclosed |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-20 | — | — | US | disclosed |
| US-8623872-B2 | Quinazolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-8623884-B2 | Quinazolinedione derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-07 | — | — | US | disclosed |
| CN-1980899-B | Quinazolinone derivatives as parp inhibitors | JANSSEN PHARMACEUTICA NV | 2013-07-24 | — | — | CN | disclosed |
| US-20080070915-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | JANSSEN PHARMCEUTICA, NV (BE) | 2008-02-14 | — | — | US | disclosed |
| CN-1980913-A | Quinazolinedione derivatives as parp inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
| CN-1980899-A | Quinazolinone derivatives as parp inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1771422-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| EP-1763518-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1763523-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006003146-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006003148-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006003150-A1 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108020-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | TSHR 3025/4885L3MBTL1 2870/4885HSD17B10 1152/4885 |
| US-20080039480-A1 | Quinazolinedione Derivatives as Parp Inhibitors | PARP1, PARP2, PARP3 | TSHR 3025/4885L3MBTL1 2870/4885HSD17B10 1152/4885 |
| US-10150757-B2 | Quinazolinone derivatives as PARP inhibitors | PARP1, PARP3, PARP2 | TSHR 4087/4885L3MBTL1 1488/4885HSD17B10 2418/4885 |
| US-20140080835-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | TSHR 4087/4885L3MBTL1 1488/4885HSD17B10 2418/4885 |
| US-20080070915-A1 | Poly(ADP-ribose)polymerase (PARP); ischemia, reperfusion injuries, neurological disorders, neuroprotectants, sensitizer for chemotherapy or radiotherapy, anticancer | PARP1, PARP2, PARP11 | TSHR 3150/4885L3MBTL1 544/4885HSD17B10 2910/4885 |
| US-20170158673-A1 | QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP3, PARP2 | TSHR 4087/4885L3MBTL1 1488/4885HSD17B10 2418/4885 |
| US-20140100239-A1 | QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | TSHR 3025/4885L3MBTL1 2870/4885HSD17B10 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.